Abstract
Background/Aims: Patients who are Helicobacter pylori antibody negative and have normal pepsinogen (PG) levels (group A of ABC (D) stratification) are considered unlikely to develop gastric cancer. This study aimed to clarify the involvement (uninfection, present infection or previous infection) of H. pylori in group A patients with early gastric cancer who underwent endoscopic submucosal dissection (ESD) by examining their background gastric mucosa endoscopically and histologically. Methods: This study included 166 patients with gastric cancer who were treated by ESD. Patients were classified according to PG levels and H. pylori antibody titers. Three biopsies (greater curvature of the antrum, lesser curvature of the middle corpus and greater curvature of the middle corpus) from group A were histologically analyzed and compared with those of groups B, C, D and after eradica-cancer is approximately 2-10% [3, 4] . However, taking mucosal atrophy into consideration, the incidence of gastric cancer in patients with no history of H. pylori infection is considerably lower. Matsuo et al. [5] reported that the frequency of H. pylori -negative carcinoma among 3,161 gastric cancer samples was 0.66%. Likewise, Ono et al. [6] reported that 0.42% of early gastric cancers developed without current or past H. pylori infection.
Serological parameters, such as pepsinogen (PG) levels, are routinely used to monitor atrophic or inflammatory conditions in the gastric mucosa. Ninety-nine percent of PG, the inactive precursor of pepsin specifically produced in the stomach, is secreted into the gastric lumen, while 1% is secreted into the blood stream [7] . PG is composed mainly of 2 biochemically and immunologically distinct isozymes (PG I and PG II). Both PG I and PG II are produced by chief and mucous neck cells in the stomach. In addition, PG II is produced by cardiac, pyloric and Brunner's gland cells [8, 9] .
Some studies have demonstrated that a low PG I concentration and PG I/II ratio are indicators of atrophic gastritis [10] [11] [12] [13] [14] . In addition, a high PG II level reflects chronic inflammation in H. pylori -related chronic gastritis [13, 14] . The ABC (D) method, which measures both H. pylori antibody titer and serum PG levels, provides an efficient evaluation of gastric cancer risk [15] [16] [17] [18] . Group A patients are classified as having normal PG levels and are negative for H. pylori antibodies. Thus, these patients are assumed to have no H. pylori infection or atrophic gastritis, with little risk of developing gastric cancer. However, in clinical practice, gastric cancer is occasionally identified in group A patients [19] . Thus, group A is considered to include both patients truly negative for H. pylori and high-risk patients. These high-risk patients may include those with past H. pylori infection or falsenegative test results for PG and/or H. pylori antibodies despite ongoing H. pylori infection. Therefore, this study aims to clarify the involvement (uninfection, present infection or previous infection) of H. pylori in group A patients with early gastric cancer who underwent endoscopic submucosal dissection (ESD) by examining their background gastric mucosa using histological (based on the updated Sydney system) and endoscopic evaluations.
Methods

Patients
Between January 2009 and September 2013, 507 consecutive patients with primary gastric cancer were treated by ESD at Okayama University Hospital. We analyzed 273 patients via histological examination as well as prior evaluation of serum H. pylori antibody titers and serum PG concentration. Patients were excluded if they had a history of upper gastrointestinal tract surgery (n = 36) or were taking proton pump inhibitors, as this could affect serum PG levels (n = 71). Therefore, 149 patients, none of whom received H. pylori eradication therapy, were enrolled in this study. Previous eradication history was decided based on the files of our hospital and the medical information of referral patients from other clinics. In addition, 17 patients with a history of H. pylori eradication therapy before ESD were included for comparison. Three biopsy samples (greater curvature of the antrum, lesser curvature of the middle corpus and greater curvature of the middle corpus) were endoscopically obtained from each patient for histological analysis.
The study was approved by the Okayama University School of Medicine Clinical Ethics Committee on Human Experiments (approval number 2,162; October 28, 2014) in accordance with the Declaration of Helsinki. Each patient provided informed consent.
Serum Measurements
Fasting blood samples were collected from all patients immediately before endoscopy. Serum H. pylori IgG antibody titers were measured using a commercially available kit (E-plate; Eiken, Tokyo, Japan). Antibody titers were measured by optical density using standards and a cutoff value of 10 U/ml according to the manufacturer's protocol. Serum PG I and PG II levels were measured using a commercial chemiluminescent enzyme immunoassay kit (Lumipulse Pepsinogen I & II; Fujirebio Inc., Tokyo, Japan). Positive cutoff values were set at PG I ≤ 70 and PG I/II ≤ 3.0 ng/ml, as previously described [20] [21] [22] .
Endoscopic Examination
Endoscopic mucosal atrophy was evaluated at the atrophic border, as described by Kimura and Takemoto [23] . This boundary between the pyloric and fundic gland regions was endoscopically recognized by differences in color and the height of the gastric mucosa between the 2 sides of the border. Gastric mucosal atrophy was classified into 3 categories: no atrophy, closed-type or opentype. And it is reported that there is a higher risk of developing gastric cancer in the case of open-type atrophy than that of closedtype atrophy [24] . As it is difficult to distinguish cases of the mild atrophy (only on antrum) and no-atrophy cases endoscopically, we perform indigo carmine dye spraying in the routine esophagogastroduodenoscopy and to diagnose no-atrophy cases for those who have smooth mucosa.
Histological Examination
Serial sections of the 3 biopsy specimens (greater curvature of the antrum, lesser curvature of the middle corpus and greater curvature of the middle corpus) were stained with hematoxylin and eosin and Giemsa. The status of the gastric mucosa was evaluated by expert pathologists. The degree of polymorphonuclear neutrophil activity and chronic inflammatory cells (mononuclear cells) indicate chronic gastritis, atrophy, IM and H. pylori density. Biopsies were classified into 4 grades according to the updated Sydney system [25] : 0, normal; 1, mild; 2, moderate; and 3, severe.
ABC (D) Stratification
Group A consisted of patients negative for H. pylori antibody and with normal PG levels, group B patients had normal PG levels and were positive for H. pylori antibody, group C patients 19 had atrophic PG levels and were positive for H. pylori antibody and group D patients had atrophic PG levels and were negative for H. pylori antibody. Clinical practice has shown that group A frequently contains high-risk patients with atrophic gastritis [19] . Therefore, group A patients were separated into those endoscopically and/or histologically diagnosed with atrophic gastritis (group A ′ ) as well as those with no atrophic gastritis who were truly negative for H. pylori infection. To clarify H. pylori involvement in group A ′ , we compared the gastric histological features of group A ′ with those of groups B, C and D, as well as patients who had a history of H. pylori eradication therapy before ESD.
Statistical Analysis
Statistical analyses for comparing categorical data were performed using Pearson's chi-square tests. A Student's t test or Wilcoxon rank sum test was used for numerical data and scored categorical data, as appropriate. A p value <0.05 was considered statistically significant. JMP statistical software (SAS Institute Inc., Cary, N.C., USA) was used for all calculations. The statistical analyses performed were verified by a qualified biostatistician. 
Results
Patient Characteristics
Characteristics of Groups A and A ′
In group A, only 2 patients (1.3%) did not have endoscopic atrophic gastritis. Histologically, these patients had no inflammation, activity, atrophy or IM at all 3 sites. Therefore, they were considered truly uninfected with H. pylori . The remaining 32 patients had endoscopic and/or histological atrophy (group A ′ ; table 2 ). This group included 24 men and 8 women with an average age of 73 years. Serum anti-H. pylori antibody titer was <5 U/ml in 26 out of 32 cases while it was <3 U/ml in 20 cases. On the other hand, all 32 patients had endoscopic atrophy, with 3 (9%) cases of closed-type atrophy and 29 (91%) cases of open-type atrophy. In group A ′ , the median PG I level was 40.4 ng/ml and the average PG II level was 7.8 ng/ml. The PG I levels of 27 patients (84%) were <70 ng/ml, and the PG II levels of 25 patients (78%) were <10 ng/ml. A urea breath test was performed for 9 group A ′ patients; all 9 patients tested negative (data not shown).
The histological characteristics of group A ′ are shown in table 3 . Ten patients were normal for inflammation at all 3 sites, and 27 patients were normal for activity at all 3 sites. By histological analysis, each patient in group A ′ had atrophy, IM or inflammation. There was no H. pylori colonization in any group A patient.
Histological Distinctions between Group A ′ and Groups B, C and D
The histological characteristics of group A ′ were compared with those of groups B, C and D, as well as those of patients who previously received eradication therapy (af- ter eradication group). The activity and inflammation scores of group A ′ were lower than those of groups B and C at all 3 sites, and were lower than those of group D ( fig. 2 a, b) . Activity scores in group A ′ and the after eradication group were almost zero ( fig. 2 a) . Regarding atrophy scores, no significant differences were detected between groups in the greater curvature of the antrum. However, in the corpus, atrophy scores of group A ′ were lower than those of groups C and D, and were similar to those of the after eradication group ( fig. 2 c) . Regarding IM, no significant difference was detected between groups except that scores of group A ′ were lower than those of group D in the greater curvature of the corpus ( fig. 2 d) .
Discussion
This retrospective study evaluated 149 patients without an apparent history of H. pylori eradication therapy and 17 patients who received prior eradication therapy, all of whom were treated for primary gastric cancer with ESD. Group A (i.e., both normal PG test and negative for H. pylori antibody) patients accounted for 23% (34 of 149 patients) of the patients without a history of eradication therapy. While there have been several reports that showed patients who developed gastric cancer due to the involvement of H. pylori infection in group A, we have not yet seen detailed study about them. We examined serum antibody titer for group A ′ patients, and then compared their status of histological gastritis with those of groups B, C, D and the group who had eradication history. As a result, we found that group A ′ patients' serum antibody was very low and that there was a similarity of status of histological gastritis in group A ′ patients and patients with eradication history. Based on this procedure, we think our study firstly proved that the most of group A ′ patients were the cases of former infection with unexpected successful eradication, not the cases of false-negative of present infection. In group A, only 2 patients (1.3%) were truly uninfected with H. pylori ; similar rates have been reported previously. Matsuo et al. [5] reported a frequency of H. pylori -negative gastric cancer of 0.66% (21 of 3,161 patients). Similarly, Ono et al. [6] reported that only 1 of 240 cases of early gastric cancer (0.42%) occurred in patients without current or past H. pylori infection. Boda et al. [19] reported that 3 of 271 patients (1.1%) with gastric epithelial neoplasms were truly uninfected with H. pylori . Thus, gastric cancer is rare in patients uninfected with H. pylori .
In this study, the remaining 32 patients (group A ′ ) were also negative for H. pylori antibodies and had normal serum PG levels. However, they each exhibited gastric atrophy via endoscopic and/or histological analyses. Ono et al. [6] reported that 14% of patients with early gastric cancer treated by ESD were negative for 5 H. pylori tests and had not received eradication therapy; these patients exhibited histological or endoscopic atrophy. Boda et al. [19] also reported that 10% of patients treated The activity and inflammation scores of group A ′ were lower than those of groups B and C at all 3 sites, and lower than those of group D in the greater curvature of the corpus ( a , b ). Activity scores in group A ′ and the after eradication group were nearly zero ( a ). Regarding atrophy scores, no significant differences were detected between groups in the greater curvature of the antrum. However, in the corpus, atrophic scores of group A ′ were lower than those of groups C and D and were similar to those of the after eradication group ( c ). Regarding IM, no significant differences were detected between groups, with the exception of the greater curvature of the corpus ( d ). A Student's t test was used to compare data. for gastric epithelial neoplasms by ESD were classified into group A ′ , and 94% of these patients had open-type atrophy diagnosed via endoscopy. Thus, present or prior infection of H. pylori can only be confirmed by observing histological or endoscopic atrophy in approximately 10-25% of patients with early gastric cancer. Therefore, the development of gastric cancer in group A ′ patients was considered to be related to H. pylori infection (present or previous infection).
As more detailed information is unclear from previous reports, the present study clarified the actual status of H. pylori infection by comparing histological data from several sites in the stomach between group A ′ and groups B, C and D as well as the group of patients with apparent prior eradication. First, in this study, the H. pylori antibody titers of 20 patients (63%) in group A ′ were <3 U/ml (the cutoff value was 10 U/ml; data not shown). Their very low H. pylori antibody titers demonstrate that titers may not indicate false-negative results. Histological analysis according to the updated Sydney system revealed similar characteristics for group A ′ patients and those with a history of H. pylori eradication therapy. These 2 groups had lower polymorphonuclear neutrophil activity as well as chronic inflammatory and atrophy scores than groups B, C and D at all 3 sites surveyed. Kodama et al. [26] conducted a 10-year follow-up study monitoring histological changes at 5 points in the gastric mucosa after H. pylori eradication. Activity scores were markedly reduced 6 months after successful eradication, nearly reaching zero. Moreover, Kodama et al. [26] also reported a gradual decrease in atrophy scores after H. pylori eradication. All sites, except the antral sites, reached a level similar to the H. pylori -negative group. In contrast, with the exception of scores for the lesser curvature of the corpus, IM scores fluctuated considerably during the entire observation period. In our study, patients in group A ′ and patients with a history of H. pylori eradication therapy showed activity scores near zero. In addition, we observed that group A ′ had lower atrophy scores than groups C and D in the lesser and greater curvatures of the corpus.
Antral atrophy was more dominant than corpus atrophy in group A ′ patients. This finding is not compatible with autoimmune gastritis, which is another cause of atrophic gastritis. When mucosal atrophy is caused by autoimmune gastritis, corpus atrophy is more dominant [27] . Thus, we hypothesize that the activity and atrophy scores of group A ′ decreased after unexpected eradication of H. pylori infection (e.g., antibiotic administration for any bacterial infection). Accordingly, many patients in group A ′ were regarded as having a history of unexpected successful eradication.
Our study had certain limitations. This was a retrospective, single-center study with a limited number of cases. Next, though biopsy regions that got consensus by the updated Sydney system were 5, we utilized lesser samples (1 sample for 3 regions) to evaluate the histologic gastritis on the background mucosa for the purpose of less invasive procedure, which can be considered another limitation. Furthermore, subjects were limited to patients with early gastric cancer who were treated with ESD. In the general population of Japan, the prevalence of H. pylori -infected patients with a history of unexpected eradication is unknown. In this study, the median patient age was 72 years. The difference in age between our patient population and that of the general population may have influenced H. pylori antibody titers and PG levels. Thus, large-scale, multicenter studies are warranted.
Though it is useful to perform endoscopic examination for atrophic gastritis as is shown in this study to clarify whether or not patients in group A are uninfected with H. pylori , it will be too difficult to put it into practice considering a problem of cost and man power. On the other hand, the ABC (D) stratification is considered to be a reliable mass screening method to examine a risk of gastric cancer in that it is simple despite several exceptional cases. It is expected to be carried out in the future. Considering that as we have extended coverage of national health insurance in Japan and there will be an increasing number of patients who undergo eradication therapy, group A patients are expected to increase more and more, we need to develop a criterion value system to examine whether or not patients in group A are uninfected with H. pylori .
In conclusion, our histological data suggest that approximately 20% of gastric cancer patients experience unexpected eradication for H. pylori and would therefore be considered high-risk patients despite having normal PG levels and testing negative for H. pylori antibodies. It is important to consider that group A includes not only low-risk patients truly negative for H. pylori , but also patients at high risk for developing gastric cancer.
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